As of June 6, 2025, Reata Pharmaceuticals Inc (RETA) reports a ROA (Return on Assets) of -60.62%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Reata Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Reata Pharmaceuticals Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2022-12-31 | -60.62% |
| 2021-12-31 | -40.46% |
| 2020-12-31 | -28.89% |
| 2019-12-31 | -42.52% |
| 2018-12-31 | -23.33% |
This slight downward trend highlights how Reata Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Reata Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Reata Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Reata Pharmaceuticals Inc (RETA) | -60.62% |
| Zoetis Inc (ZTS) | 17.46% |
| Merck & Co Inc (MRK) | 14.62% |
| Eli Lilly and Co (LLY) | 13.45% |
| Johnson & Johnson (JNJ) | 7.81% |
| Royalty Pharma PLC (RPRX) | 4.71% |
Compared to its competitors, Reata Pharmaceuticals Inc's ROA (Return on Assets) is among the lowest compared to peers, suggesting potential inefficiency in asset utilization.